Office for Technology Commercialization

Tissue-Equivalent Replacement Heart Valves

Technology #97127

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Heart ValvesTissue-Equivalent ValveReplacement Heart Valve
Robert Tranquillo, Ph.D.
External Link (
Managed By
Raj Udupa
Technology Licensing Officer 612-624-3966
Patent Protection
US Patent 6,666,886

Issues with Biologic and Mechanical Heart Valves

Tissue-equivalent cardiovascular valves provide a safer, biocompatible valve replacement therapy that is also suitable for use in children. While both mechanical and biologic replacement heart valves have been used to treat this problem, the complication rate is high, particularly in pediatric patients, where current replacement valves are not able to grow with the child.
Valvular heart disease occurs in an estimated 2.5% of the population in the US due to congenital heart defects and the aging population; many of these patients require heart valves be replaced.

MN-IP Try and Buy
This technology is available via a standard negotiated license agreement. Contact Raj Udupa for specific details.

Tissue-Equivalent Heart Valves

A method has been developed for the fabrication of a tissue-engineered multi-leaflet cardiovascular valve. The leaflets’ collagen (or fibrin) fibrils are circumferentially aligned as seen in native leaflets. The alignment mimics the native alignment and provides a "template for remodeling" upon implantation. Fibrillar biopolymer gel and tissue cells are used to create the valve, allowing the valve to grow with the patient without the risk of rejection seen in non-biocompatible devices.


  • Safer valve replacement with fewer complications and a lower mortality rate
  • Valve has a template for remodeling when placed within patient
  • Biocompatible
  • Valve can grow with patient, suitable for use in juveniles

Related Technology
20120236 Biological Heart Valves and Arteries for Children